First patient dosed in the pediatric cohort of the Phase 1/2 trial of OPGx-LCA5; initial data on the cohort anticipated by Q3 2025New 12-month ...
Opus Genetics (IRD) announced that the first pediatric patient was dosed in its ongoing Phase 1/2 clinical trial evaluating OPGx-LCA5, its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback